Galapagos Completes Works Council Consultation for Cell Therapy Business Wind-down

12:14 AM EST, 01/06/2026 (MT Newswires) -- Galapagos (GLPG.AS) completed consultation with the works council in Belgium and the Netherlands regarding its plan to wind down its cell therapy business. The plan will result in the closure of the biotechnology company's sites in the Netherlands, Switzerland, the US, and China, affecting 365 employees, according to a Monday release. Amid the wind-down, the company will retain management of its non-cell therapy activities, including the TYK2 program GLPG3667. It will continue to be based in Mechelen, Belgium, and keep ownership of hubs in Chicago and San Francisco in the US. Galapagos noted that it will launch a strategic review for GLPG3667, with plans to evaluate options for the program, including resumption of partnering and expediting developments in dermatomyositis and potentially other severe autoimmune indications.